Orforglipron.

How it works

Orforglipron binds and activates the GLP-1 receptor, the same class B G-protein-coupled receptor engaged by semaglutide, liraglutide and the GLP-1 arm of tirzepatide, producing glucose-dependent insulin secretion, slowed gastric emptying, suppressed glucagon and reduced appetite. The pharmacologically interesting part is how it does this without being a peptide. Work published in Science Translational Medicine (2024, PMID 39693407) characterises the basis for non-peptide agonism at this receptor: the molecule occupies a site that permits receptor activation from a small synthetic scaffold rather than mimicking the native hormone's full peptide sequence. Because it is not a peptide, it is not degraded in the gut the way oral peptide formulations are, which is why it can be taken as a conventional tablet with no food or water timing restrictions, unlike oral semaglutide.

The evidence

Human evidence is substantial and spans phase 2 through phase 3 in both obesity and type 2 diabetes. A phase 2 trial in adults with obesity (NEJM 2023, PMID 37351564) established dose-dependent weight reduction, and a parallel phase 2 programme in type 2 diabetes reported in The Lancet (2023, PMID 37369232) showed reductions in HbA1c and body weight. Phase 3 results in obesity were published in the New England Journal of Medicine (2025, PMID 40960239), and a separate NEJM report (2025, PMID 40544435) covered early type 2 diabetes. A head-to-head trial against oral semaglutide in adults with type 2 diabetes appeared in The Lancet (2026, PMID 41765029), and a randomized phase 3 maintenance trial was published in Nature Medicine (2026, PMID 42120723). ACHIEVE-5, adding orforglipron to titrated insulin glargine, was reported in JAMA (2026, PMID 42251769). This is a considerably more complete human evidence package than almost anything else discussed in peptide communities, which is the point worth taking from it.

Safety profile

The adverse-event profile reported across the trials is the familiar GLP-1 class pattern, dominated by gastrointestinal effects: nausea, vomiting, diarrhoea and constipation, generally most pronounced during dose escalation and often diminishing with time. Discontinuation for gastrointestinal reasons occurred in the trials. As an approved product it carries a prescribing label with the full contraindication and warning set for the GLP-1 receptor agonist class, and that label, not this page, is the authoritative safety document. Because it is a prescription medicine, safety monitoring happens through a prescriber rather than self-management, which is a meaningful difference from the research-use-only compounds elsewhere on this site.

Regulatory status

FDA-approved 1 April 2026 as Foundayo (orforglipron) for chronic weight management in adults with obesity, or with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It is a prescription medicine. Approval is indication-specific: an approval for chronic weight management is not a validation of any other use it may be marketed or discussed for. Regulatory status elsewhere in the world varies and should be checked locally.

By the numbers

• 01FDA-approved 1 April 2026 as Foundayo for chronic weight management; developed by Eli Lilly.
• 02A small-molecule, non-peptide GLP-1 receptor agonist, not a peptide, despite acting on the same receptor as the injectable GLP-1 peptides.
• 03Taken orally once daily as a conventional tablet, with no food or water timing restrictions, unlike oral semaglutide.
• 04Phase 3 evidence published in NEJM, The Lancet, Nature Medicine and JAMA across obesity and type 2 diabetes.
• 05Prescription-only. Nothing on this page is a dose recommendation or a substitute for the prescribing label.

Sources

Every factual claim above resolves to a real, published source.

1. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentNew England Journal of Medicine, 2025. Phase 3 obesity results. · randomized controlled trial · indexed →
2. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesityNew England Journal of Medicine, 2023. Phase 2 obesity trial. · randomized controlled trial · indexed →
3. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 DiabetesNew England Journal of Medicine, 2025. · randomized controlled trial · indexed →
4. Efficacy and safety of oral orforglipron in patients with type 2 diabetesThe Lancet, 2023. Multicentre phase 2 trial. · randomized controlled trial · indexed →
5. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutideThe Lancet, 2026. Head-to-head trial. · randomized controlled trial · indexed →
6. Orforglipron for maintenance of body weight reductionNature Medicine, 2026. Double-blind randomized phase 3. · randomized controlled trial · indexed →
7. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: ACHIEVE-5JAMA, 2026. Randomized trial. · randomized controlled trial · indexed →
8. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronScience Translational Medicine, 2024. · journal article · indexed →

See all 8 indexed papers for Orforglipron in the research library →